A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

  • End date
    Mar 20, 2024
  • participants needed
  • sponsor
Updated on 21 April 2022


Phase II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) combined with Docetaxel in Advanced Non-Small Cell Lung Cancer whose disease has progressed after prior platinum doublet chemotherapy and anti-PD-1/PD-L1 monoclonal antibody

Condition Advanced Non-small Cell Lung Cancer
Treatment docetaxel, AK104
Clinical Study IdentifierNCT05215067
Last Modified on21 April 2022


Yes No Not Sure

Inclusion Criteria

18 to 75 years old
Have a life expectancy of at least 3 months
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Has a histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC
Has radiographic progression after prior platinum doublet chemotherapy and anti-PD-1/PD-L1 monoclonal antibody (mAb) administered
No known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations
Has at least 1 measurable lesion per RECIST 1.1 assessed by investigator
Has adequate organ function

Exclusion Criteria

Undergone major surgery within 30 days prior to the first dose of study treatment
Active central nervous system (CNS) metastases
History of active autoimmune disease that has required systemic treatment in the past 2 years (i.e.,corticosteroids or immunosuppressive drugs)
Active Hepatitis B or Hepatitis C
Received previous immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy and other treatments targeting the mechanism of tumor immunity
Has received treatment with docetaxel
History of severe bleeding tendency or coagulation disorder
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note